Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ondansetron Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

NCT01442376
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
Up to 16 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Sep 23, 2026, 2:42 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

NCT02614586
View directory record Official record
Conditions
Schizophrenia
Interventions
TAK-058, Ondansetron, TAK-058 Placebo, Ondansetron Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

NCT01450826
View directory record Official record
Conditions
Nausea, Vomiting, Glioma
Interventions
aprepitant, ondansetron
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

NCT03973047
View directory record Official record
Conditions
Nausea
Interventions
Bremelanotide, Zofran, Placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)

NCT00027079
View directory record Official record
Conditions
Alcoholism
Interventions
ondansetron (Zofran), naltrexone (ReVia), Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Sep 23, 2026, 2:42 PM EDT
Not listed Phase 2 Interventional

A Study in Patients With Major Depressive Disorder

NCT03642964
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
CTC-501
Drug
Lead sponsor
Chase Therapeutics Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Ondansetron for the Treatment of Methamphetamine Dependence - 1

NCT00040053
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Ondansetron
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Chula Vista, California • Costa Mesa, California • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

NCT01449188
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
ondansetron, moxifloxacin, saline
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 23, 2026, 2:42 PM EDT
Completed No phase listed Observational Results available

Ondansetron and the QT Interval In Adult Emergency Department Patients

NCT01759420
View directory record Official record
Conditions
Ondansetron
Interventions
Ondansetron
Drug
Lead sponsor
C.R.Darnall Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Fort Hood, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 4 Interventional Results available

Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department

NCT02760069
View directory record Official record
Conditions
Nausea
Interventions
Inhaled isopropyl alcohol, Oral ondansetron, Inhaled normal saline, Oral placebo
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Sep 23, 2026, 2:42 PM EDT
Terminated Phase 4 Interventional Results available

Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery

NCT02724033
View directory record Official record
Conditions
Anesthesia, Pediatrics, Surgery
Interventions
regional nerve block, Antiemetic
Procedure · Drug
Lead sponsor
Indiana University
Other
Eligibility
1 Year to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia

NCT00149734
View directory record Official record
Conditions
Schizophrenia
Interventions
Ondansetron followed by placebo, Placebo followed by Ondansetron
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder

NCT02354703
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Ondansetron Treatment for Alcoholism

NCT00000443
View directory record Official record
Conditions
Alcoholism
Interventions
ondansetron (Zofran)
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
25 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg

NCT00649532
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron Tablets 24 mg, Zofran® Tablets 24 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 4 Interventional Results available

Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting

NCT03297021
View directory record Official record
Conditions
Post-operative Nausea and Vomiting
Interventions
Ondansetron 4 MG, Ondansetron 8mg
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking

NCT00183222
View directory record Official record
Conditions
Alcohol Dependence
Interventions
naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

NCT01031498
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
Interventions
Ondansetron, Palonosetron
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Ondansetron on Brain Function

NCT02460341
View directory record Official record
Conditions
Brain Function, Healthy Adults
Interventions
ondansetron, placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 3 Interventional

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

NCT00006348
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ondansetron, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 23, 2026, 2:42 PM EDT
Completed Phase 4 Interventional

Haloperidol for the Treatment of Nausea and Vomiting in the ED

NCT04764344
View directory record Official record
Conditions
Vomiting, Nausea, Abdominal Pain, Cannabis Use
Interventions
Haloperidol, Ondansetron
Drug
Lead sponsor
Western Michigan University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 23, 2026, 2:42 PM EDT
Terminated Phase 4 Interventional Results available

Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

NCT03262038
View directory record Official record
Conditions
Pruritus, Nausea/Vomiting
Interventions
Ondansetron, Placebo Comparator
Drug
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 23, 2026, 2:42 PM EDT
Withdrawn Not applicable Interventional

Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting

NCT00699894
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
aprepitant 40 mg, ondansetron 4 mg
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 25 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2013 · Synced Sep 23, 2026, 2:42 PM EDT
Recruiting Phase 2Phase 3 Interventional

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

NCT06382012
View directory record Official record
Conditions
Nausea and Vomiting, Nausea, Vomiting
Interventions
Fosaprepitant 150 mg, Ondansetron 4 mg
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 23, 2026, 2:42 PM EDT